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Objective Type 2 diabetes is associated with an increased risk of fracture. Any factor that 
incrementally increases this risk should be taken into account when individualizing treatment. 
Hypoglycemia is a common complication of antidiabetes medications and suggested as a risk 
factor for fractures, yet its real-life clinical impact is unclear. 
Design A population-based, retrospective open cohort study using routinely collected data 
between 1st of January 1995 and 1st of May 2016 in The Health Improvement Network (THIN) 
database. 
Methods Patients with type 2 diabetes mellitus with documented hypoglycaemic events were 
compared to randomly matched patients with type 2 diabetes mellitus without documented 
hypoglycaemic events matched to exposed patients on age, sex, duration of diabetes and BMI.  
The primary outcome was any incident fracture. Secondary outcome was incident fragility 
(osteoporotic) fracture.  
Results A total of 41,163 patients with type 2 diabetes were included: 14,147 patients in the 
exposed cohort and 27,016 patients in the unexposed cohort. Patients with a documented 
hypoglycaemic event were significantly more likely to sustain any fracture compared to 
patients with no record of hypoglycemic events: adjusted IRR 1.20 (95% CI 1.12-1.30; p < 
0.0001). Patients who had a documented hypoglycaemic event were significantly more likely 
to suffer a fragility fracture compared to controls: adjusted IRR 1.24 (95% CI 1.13-1.37; p < 
0.0001).  
Conclusions Hypoglycaemic events are a significant risk factor for fractures in patients with 
diabetes mellitus. This observation is clinically relevant when individualizing targets for 






Each year in the UK 1.8 million fractures occur with an annual incidence of about 3.6% and a 
lifetime prevalence of approximately 40% 1-3. The annual cost in the UK for hip fractures alone 
including medical and social care is about £2 billion 4. 
Despite their apparently normal areal bone density, patients with type 2 diabetes mellitus have 
an increased risk of fragility (osteoporotic) fractures 5-9. This paradox has been partly attributed 
to impaired bone microarchitecture and accumulation of advanced glycation end products 6. 
However, patients with type 2 diabetes mellitus may also be at an increased risk of falls, as a 
result of concomitant medications (such as antihypertensive treatment),  peripheral neuropathy 
due to diabetes and associated impaired mechano-sensation, orthostatic hypotension caused by  
autonomic neuropathy and possibly hypoglycaemic events associated with antihyperglycaemic  
therapy. Considering that there are 4 million people living with type 2 diabetes mellitus in the 
UK and by 2025 it is estimated that the number will rise to 5 million 10, 11, it is important to 
further our understanding regarding the underlying risk factors that increase the risk of fractures 
in type 2 diabetes mellitus patients. 
Hypoglycaemia is one of the main complications of diabetes treatment and is associated with 
serious adverse events 12. The majority of studies exploring the association between 
hypoglycaemic events and fracture risk have used commercial health claims databases 13-15 or 
national hospital and psychiatric registers 16. The latter patients constitute a distinct subset and 
these findings may not be applicable to the general diabetic population. Thus, there is paucity 
of evidence regarding the association of hypoglycaemia and fracture in a general population. 
Hence, we aimed to assess the association between hypoglycaemia and risk of fracture in 
patients with type 2 diabetes mellitus using UK primary care data.  
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Subjects and Methods 
Study design A population-based, retrospective open cohort study in which patients with type 
2 diabetes mellitus with documentation of any hypoglycaemic event were compared to 
randomly matched patients with type 2 diabetes mellitus without documented hypoglycaemic 
events. Age, gender, BMI and duration of diabetes mellitus were used as the matching 
parameters. 
Data source Data for this study was obtained from The Health Improvement Network (THIN) 
database, a UK general practice electronic database. Data are entered by general practitioners 
during each consultation using Read Codes, a hierarchical coding system for structured storage 
of information 17. More than 675 practices across the UK contribute data to THIN18.  THIN 
data are generalizable to the UK for major health conditions 19 and have been used for studies 
exploring hypoglycaemic events in patients with diabetes 20.  
Study population  Adult patients aged ≥ 18 with type 2 diabetes mellitus registered in general 
practices contributing to THIN during the study period (1st of January 1995 to 1st of May 2016) 
were eligible. 
Observation period A patient was eligible one year after the latest of the following dates: 1) 
registration in the practice (registration date); 2) introduction of Electronic Medical Record 
(EMR date); and 3) Acceptable Mortality Recording (AMR) date. AMR is an indicator of when 
practices started to record information consistently and in a timely manner 21. A one year latent 
period is applied to ensure there was sufficient time to record all important covariates. Follow-
up end date (exit date) was the earliest of transfer date (when patient left the practice), death 
date, first documentation of outcome i.e. fracture (outcome date), or study end date.  
Exposed cohort Individuals were included in the exposed cohort if they were 18 years or older, 
had a diagnosis of type 2 diabetes mellitus and a documented hypoglycaemic event. Patients 
with a history of any fracture were excluded. The exposed cohort was followed up from the 
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date at which they had a documented hypoglycaemic event, which was defined as the index 
date for the exposed patient.  
Unexposed cohort Adult patients with type 2 diabetes mellitus who did not have a documented 
hypoglycaemic event were eligible for inclusion in the unexposed (control) group. For each 
exposed patient up to two unexposed controls were randomly selected from patients registered 
in the same participating general practice. Controls were individually matched to cases on age 
at index date (within one year), sex, documented duration of diabetes (to within 3 years) and 
BMI (+/- 2kg/m2). The index date of the unexposed patients was the same as the index date of 
the corresponding exposed patients they were matched on to ensure immortality time bias did 
not influence our analysis. Patients with a documented history of previous fractures were 
excluded. 
Outcomes and Covariates Primary outcome was any fracture (fracture at any site during the 
observation period). Secondary outcome was fragility fracture (fractures at hip, wrist, spine 
and humerus were considered as such). Diagnosis of diabetes mellitus, fractures and 
hypoglycaemic events were determined by Read codes using previously published 
methodologies and definitions noted in literature 22-24. 
Potential confounders were used as model covariates (in addition to matching parameters) and 
were selected on the basis of biological plausibility. These covariates were Townsend 
deprivation index (a measure of social deprivation), smoking status, Charlson Comorbidity 
Index (which includes diabetic complications such as peripheral neuropathy and retinopathy), 
HbA1c, insulin use 25, bisphosphonate use, systemic steroids, hyperthyroidism or Graves’ 
disease, renal impairment, alcohol intake, glitazones use, antihypertensive medications and 
stroke and TIA. 
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Statistical analysis  The study cohort was described using appropriate descriptive statistics. 
Incidence of the outcome of interest was compared between the exposed and unexposed group. 
Incidence Rate Ratios (IRR) were derived using Poisson regression adjusting for covariates. 
The covariates were age, sex, BMI, Townsend deprivation index, smoking, Charlson 
Comorbidity Index, HbA1c, Insulin use, bisphosphonate use, systemic steroids prescriptions, 
hyperthyroidism or Graves’ disease, renal impairment and antihypertensive medications. 
Statistical significance was determined at p < 0.05. 
A sensitivity analysis including only incident diabetes patients (patients who developed 
diabetes after becoming eligible to participate in the study) was conducted. This was to explore 
impact of any biases of under-recording of hypoglycaemic consultation in patients who had 
diabetes either before the practice became eligible to participate or before they registered with 
the practice. In an analysis limited to the exposed incident hypoglycaemic patients we explored 
if an increasing number of documentation of hypoglycaemia per year was associated with 
increased risk of fractures. For this analysis four groups were determined based on quartiles of 
the exposure of interest. Exposure of interest was defined as number of hypoglycaemic 
presentation per year of follow-up. The groups were hypoglycaemic recording once in more 
than 4.0 years (low incidence:quartile 1), once in 2.0 to 4.0 years (quartile 2), once in 0.85 to 
2.0 years (quartile 3) and once in less than 0.85 years (high incidence: quartile 4). 
Results 
 A total of 41,163 patients with type 2 diabetes were included in the study population; 14,147 
patients were included in the exposed cohort (patients with a documented hypoglycaemic event 
at their index date), and 27,016 patients were included in the unexposed cohort (Table 1). A 
flow chart summarising the formation of the study population is presented in the 
Supplementary Figure 2 (Appendix). Across the whole study population at baseline, 52.3% 
were male; median (interquartile range) age was 69.4 (58.2-77.7) years; mean (standard 
 9 
deviation [SD]) BMI was 29.5 (6.1) kg/m2; mean (SD) HbA1c was 59.9 (17.8) mmol/mol; and 
mean (SD) duration of diabetes was 10.9 (8.3) years. Patients in the exposed group had poorer 
glycaemic control, had more comorbidities, were more likely to be on systemic steroids, and 
were twice as likely to be taking insulin compared to patients in the unexposed group. For all 
fractures, median (IQR) and mean (SD) follow up were 3.3 (1.4-6.3) and 4.3 (3.5) years 
respectively; for fragility fractures, median and mean follow up were 3.3 (1.4-6.3) and 4.3 (3.5) 
years respectively. During the observation period, a total of 3,215 fractures (1,238 in patients 
with documented hypoglycemic events) were recorded, out of which 1,957 (758 in patients 
with documented hypoglycemic events) were considered to be fragility fractures. 
Patients with type 2 diabetes who had a documented hypoglycaemic event were significantly 
more likely to suffer any fracture compared to patients with type 2 diabetes in the unexposed 
matched cohort: crude IRR 1.29 (95% CI 1.20 to 1.38; p < 0.0001). Adjusting for preselected 
covariates (age, sex, BMI, Townsend score, smoking status, alcohol consumption, HbA1c, 
Charlson Comorbidity Index, presence of Graves’ disease or hyperthyroidism, and use of 
insulin, systemic steroids, bisphosphonates or glitazones), the findings remained significant 
[adjusted IRR 1.20 (95% CI 1.12 to 1.30; p < 0.0001) (Table 2 and Figure 1)]. Findings 
remained significant in the sex-specific analysis [men 1.16 (95% CI 1.02-1.32; p = 0.023); 
women 1.23 (95% CI 1.12-1.34; p<0.001)]. Similarly, the effect sizes did not change in women 
when age was also taken into consideration [(women with age ≤65 years: 1.20 (95% CI 1.02–
1.41; P = 0.032) and age >65 years: 1.25 (95% CI 1.12–1.40; P < 0.001).]. In men, the risk was 
more evident in those aged above 65 years [age<=65 years 1.11 (95%CI 0.89-1.37; p=0.35) 
and  age>65 years 1.20 (95%CI 1.02-1.41;p=0.027)]. 
Patients with type 2 diabetes and a documented hypoglycaemic event were significantly more 
likely to sustain fragility fracture compared to patients with diabetes in the unexposed cohort 
[crude IRR 1.29 (95% CI 1.18 to 1.42; p < 0.0001) and aIRR 1.24 (95% CI 1.13 to 1.37; p < 
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0.0001) (Table 2 and Figure 1)]. Findings were significant in women but did not reach statistical 
significance in men in the sex-specific analysis [men 1.19 (95% CI 1.00-1.42; p = 0.053); 
women 1.27 (95% CI 1.13-1.42; p<0.001)]. Effect sizes were similar for both sexes below and 
above 65 years [women: age<=65 years 1.26 (95%CI 1.00-1.58; p=0.053) and  age>65 years 
1.28 (95%CI 1.12-1.46;p<0.001); and men: age<=65 years 1.16 (95%CI 0.82-1.64; p=0.400) 
and  age>65 years 1.20 (95%CI 0.98-1.47;p=0.078)]. 
Sensitivity analysis, in which only patients with incident type 2 diabetes were included (Table 
3), confirmed the difference in rates of fragility fracture between those with and without a 
documented hypoglycaemic event [crude IRR 1.45 (95% CI 1.20 to 1.76; p < 0.0001); aIRR 
1.33 (95% CI 1.08 to 1.67; p = 0.007)]. Similarly, when all fractures were considered, crude 
IRR was found to be increased to 1.39 (95% CI 1.20 to 1.61; p < 0.0001), and adjusted IRR to 
1.26 (95% CI 1.08 to 1.47; p = 0.004) (Table 3). 
To explore a potential exposure-outcome relationship, a further analysis limiting to incident 
exposed patients alone was performed. This analysis suggested a gradient increase in fragility 
fracture with an IRR of 2.16 (95% CI 1.35 to 3.46) in quartile 2, IRR of 3.62 (95%CI 2.27 to 
5.79) in quartile 3 and IRR of 9.35 (95%CI 5.79 to 15.10) in quartile 4 in comparison to quartile 
1.  A similar trend was also noted for any fractures, IRR of 2.16 (95% CI 1.51 to 3.09) in 
quartile 2, IRR of 3.86 (95%CI 2.71 to 5.49) in quartile 3 and IRR of 10.23 (95%CI 7.11 to 
14.74) in quartile 4. 
Discussion 
In this population-based study using a large UK primary care database, hypoglycaemia was 
associated with a statistically significant (and robust to sensitivity analyses) 20% increase in 
the risk of fractures. 
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A recent meta-analysis of observational studies reported increased odds of fracture in patients 
with documented hypoglycaemic events 12. However, there are important differences between 
our study the studies included in the meta-analysis. Importantly, in the study by Johnston et al 
14
, the estimate of which was the most influential on the meta-analysis (assigned the more 
weight), hypoglycaemic events were allowed to occur at any time during evaluation period, 
including after fracture; while in our study the direction of the relationship is clear as the 
hypoglycaemic events occurred before the occurrence of the fractures. Moreover, in the study 
by Rajpathak et al 13, only sulfonylurea users and hip fractures were considered, while our 
study included all fractures and a wider population of patients with type 2 diabetes mellitus 
receiving any treatments including insulin, which has been shown to be associated with 
increased fracture risk 26.  A meta-analysis reported that  patients with T2DM had a greater risk 
of low-energy fracture, especially of the hip, yet identified the presence of publication bias 27.  
Collectively, these observations may indicate a need for caution in the interpretation of the 
findings of this meta-analysis and justify the need for this study. Finally, our estimate is rather 
moderate in comparison with the 70% increase in the risk of hip fracture reported in a recent 
study perfomed in patients from Taiwan with severe hypoglycemia 28. However, the differences 
in ethnic background, intensity of hypoglycemic events and site of fractures explored may 
account for the difference in the magnitude of effect. 
In the ACCORD trial, intensive glycaemic control was associated with increased frequency of 
hypoglycaemia compared to standard glycaemic therapy (16.2 vs. 5.1%)  29. However, 
intensive glycaemic control did not increase the risk of non-spinal fractures or falls in the 
ACCORD trial compared to the control arm 29. Several differences between the studies could 
explain the discrepancies between the results of our study and that of ACCORD. The ACCORD 
trial population was highly selective and excluded patients at high risk of hypoglycaemia, while 
our study was population based. In addition, this secondary analysis for the ACCORD trial 
 12
only included non-spinal fractures while our study included all fractures. The follow-up 
duration was also much longer in our study compared to ACCORD. Finally, the ACCORD 
BONE was not adequately powered to detect a 20% increase in the relative rate of fractures 
(similar to what reported in our study) as the authors stated in their publication 29. 
There are several plausible explanations for the observed increase in the risk of fractures in 
patients with hypoglycaemia. Apparently, hypoglycaemia might increase the risk of falls, yet 
the data in ACCORD BONE did not show an increase risk of falls in patients in the intensive 
glycaemic control arm, although this could be attributable to recall bias 29. As an alternative 
explanation, hypoglycaemia can also occur in the context of autonomic neuropathy resulting 
in reduced hypoglycaemia awareness and autonomic neuropathy could result in postural 
hypotension and increased risk of falls. In addition, hypoglycemia has also been proposed as a 
sign of frailty, while simpler explanations (such as hypoglycaemic events leading to road traffic 
accidents resulting in fractures) should also be taken into account. However, this study was not 
designed to explore the underlying mechanism explaining the association of hypoglycaemia 
and fractures; this is an area for future study. 
The findings of the present study should be interpreted in the context of its limitations. It should 
be acknowledged that this is retrospective evidence and caution for associated bias should be 
applied. Although the study was designed to minimize its effect by using a representative 
sample of the UK population, following a fracture site and medication-agnostic approach, 
ascertaining the temporal sequence of exposure and outcome, and matching on key 
determinants of fracture risk (namely age, sex and BMI) as well as diabetes duration, residual 
bias including outcome definition may still be present. Reassuringly, our estimates were robust 
to the adjustment for covariates including medications (insulin, corticosteroids, 
bisphosphonates and glitazones), basic demographics, lifestyle and renal function. To further 
eliminate the risk of bias, we performed a sensitivity analysis limiting to incident cases with 
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diabetes mellitus, which also confirmed the robustness of our findings. Finally, a higher 
prevalence of diabetes complications in the insulin-treated patients may be an additional 
contributing factor to the apparent increase of the incidence of fractures in this subset of 
patients. However, the selection of diabetes duration as a matching parameter ensures a similar 
period for any development of any diabetes-related complication between patients and controls 
and, thus, may offset (at least in part) any potential imbalance. Of note, it was no feasible to 
asses  the severity of hypoglyceamic events  (levels of hypoglycemia) due to the nature of data. 
Finally, misclassification bias, differences in the definition and documentation of 
hypoglycaemia across practices, unmeasured confounding, missing data, and changing 
eligibility over time should also be taken into consideration when interpreting the results of 
real-world data. 
The clinical ramifications of the study may be relevant in the management of diabetes mellitus. 
Treatments that do not increase the risk of hypoglycaemia would be preferable particularly in 
patients with high risk of fractures. In addition, when considering the individualized HbA1c 
treatment target the association between hypoglycaemia and fractures could be taken into 
account and a higher HbA1c target may be advisable in a patient with increased risk of fracture. 
Using the same line of reasoning, a “drug holiday” could be deterred in the management of 
osteoporosis in a patient with diabetes mellitus, in whom diabetes complications are present or 
frequent hypoglycaemic events are present or expected. 
In conclusion, the risk of any fracture and fragility fracture were found to be significantly 
higher in patients with type 2 diabetes mellitus and incident hypoglycaemia compared to those 
without hypoglycaemia. Treatment strategies to reduce the risk of hypoglycaemia might 
contribute to lowering this increased risk of fracture. These findings may be clinically relevant 
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Male 7355 (52.0%) 14166 (52.4%) 
Female 6792 (48.0%) 12850 (47.6%) 
   
Age  
Mean (SD) 66.8 (15.0) 67.1 (14.5) 
Median (IQR) 69.3 (57.9 - 77.8) 69.4 (58.4 - 77.7) 
   
BMI categories 
<25kg/m2 3337 (23.6%) 5873 (21.7%) 
25-30Kg/m2 4895 (34.6%) 9833 (36.4%) 
>30Kg/m2 5488 (38.8%) 10452 (38.7%) 
missing or implausible values 427 (3.0%) 858 (3.2%) 
   
Townsend score 
1 2678 (18.9%) 5568 (20.6%) 
2 2728 (19.3%) 5475 (20.3%) 
3 2996 (21.2%) 5588 (20.7%) 
4 2873 (20.3%) 5474 (20.3%) 
5 2273 (16.1%) 3841 (14.2%) 
missing or implausible values 599 (4.2%) 1070 (4.0%) 
   
HbA1c categories  
≤47.5 mmol/mol 2479 (17.5%) 5674 (21.0%) 
47.5-58.5 mmol/mol 3785 (26.8%) 7930 (29.4%) 
58.5-69.4 mmol/mol 2438 (17.2%) 4270 (15.8%) 
≥69.4 mmol/mol 3202 (22.6%) 4874 (18.0%) 
missing or implausible values 2243 (15.9%) 4268 (15.8%) 
   
 
Smoker 
yes 2015 (14.2%) 3755 (13.9%) 
   
Alcohol 
Non-drinker 4689 (33.1%) 8195 (30.3%) 
Drinker 7952 (56.2%) 16619 (61.5%) 
Excessive drinker 590 (4.2%) 770 (2.9%) 
missing or implausible values 916 (6.5%) 1432 (5.3%) 








>90 (Stage 1) 2752 (19.5%) 5593 (20.7%) 
60-90 (Stage 2) 6053 (42.8%) 12853 (47.6%) 
30-59 (Stage 3) 3992 (28.2%) 6704 (24.8%) 
<30 (Stage 4) 796 (5.6%) 761 (2.8%) 
missing or implausible values 554 (3.9%) 1105 (4.1%) 
   
Charlson Comorbidity Index categories 
1 5715 (40.4%) 12809 (47.4%) 
2 3502 (24.8%) 6589 (24.4%) 
3 2275 (16.1%) 4040 (15.0%) 
≥ 4  2655 (18.8%) 3578 (13.2%) 
   
Baseline Medical Conditions  
Graves or Hyperthyroidism 306 (2.2%) 513 (1.9%) 
Cardiovascular Disease 5,158 (36.5%) 8,835 (32.7%) 
Documented Osteoporosis 335 (2.4%) 564 (2.1%) 
   
Drugs 
Insulin 6188 (43.7) 5646 (20.9) 
Metformin 6906 (48.8) 13534 (50.1) 
Sulfonylureas 5852 (41.4) 8114 (30.0) 
Acarbose  101 (0.7) 193 (0.7) 
DPP4i 695 (4.9) 1082 (4.0) 
Glinides  77 (0.5) 117 (0.4) 
Glitazones  1154 (8.2) 2165 (8.0) 
GLP1-RA  145 (1.0) 347 (1.3) 
SGLT2i 31 (0.2) 54 (0.2) 
Systemic steroids 752 (5.3) 806 (3.0) 
Biphosphonates 387 (2.7) 623 (2.3) 
Antihypertensives 10603 (74.9) 19833 (73.4) 
BMI: Body mass index, DPP-4i: Dipeptidyl peptidase-4 inhibitors, eGFR: estimated glomerular filtration rate, 
GLP1-RA: Glucagon-like peptide-1 receptors agonists, HbA1c: Glycated haemoglobin A1c, SGLT2i : Sodium-
glucose co-transporter-2 inhibitors,  
Townsend deprivation score is a composite score with a maximum total score of 94 to measure 13 categorises of 
deprivation (Townsendj 1987). This score is categorised into quintiles ranging from least deprived to most 











Outcome Exposure N (%) Person 
years 
Incidence rate (per 
1000 person years) 
Incidence rate 
ratio  (95% CI) 
P Adjusted Incidence 
rate ratio (95% CI) 
P 
         
All fractures         
 
Hypoglycaemia 1238 (8.8) 55931.6 22.1 1.29 (1.20 - 1.38) <0.0001 1.20 (1.12 - 1.30) <0.0001 
 
No hypoglycaemia  1977 (7.3) 115001.5 17.2 1  1  
 
        
Fragility fractures         
 Hypoglycaemia 758 (5.4) 57607.3 13.2 1.29 (1.18 - 1.42) <0.0001 1.24 (1.13 - 1.37) <0.0001 
 No hypoglycaemia  1199 (4.4) 117860.7 10.2 1  1  
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Table 3: Risk of fragility fracture and any fracture in patients with incident type 2 diabetes and documented hypoglycaemia compared 
to those without 
Outcome Exposure N (%) Person 
years 
Incidence rate (per 
1000 person years) 
Incidence rate 
ratio  (95% CI) 
P Adjusted Incidence 
rate ratio (95% CI) 
P 
         
All fractures         
 
Hypoglycaemia 282 (6.9) 15383.2 18.3 1.39 (1.20 - 1.61) <0.0001 1.26 (1.08 - 1.47) 0.004 
 
No hypoglycaemia  488 (5.4) 37057.9 13.2     
 
        
Fragility fractures         
 Hypoglycaemia 165 (4.1) 15765.2 10.5 1.45 (1.20 - 1.76) <0.0001 1.33 (1.08 - 1.63) 0.007 
 No hypoglycaemia  272 (3.0) 37737.9 7.2     







Figure 1. Cumulative incidence for all fractures and fragility fractures in patients presenting 
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